The Axillary Hyperhidrosis Market is set for dynamic growth, with prominent players such as Botanix Pharmaceuticals, Sound Surgical Technologies, Dr. August Wolff GmbH, Medy-Tox, Journey Medical Corporation, and others leading the way. Additional contributors include Persōn Covey, Stratus Pharmaceuticals, Allergan, AbbVie, Brickell Biotech, Dermavant Sciences, Dermata Therapeutics, Viatris, and Candesant Biomedical.
DelveInsight’s latest report, “Axillary Hyperhidrosis Market Insights, Epidemiology, and Market Forecast – 2032”, provides a deep dive into the disease landscape, including historical data, current trends, and forecasts for the US, EU4 (Germany, Spain, Italy, France), the UK, and Japan.
? To explore in detail the Axillary Hyperhidrosis market scenario, drug developments, treatment uptake, and epidemiology insights, click here: Axillary Hyperhidrosis Market Forecast
Key Highlights from the Axillary Hyperhidrosis Market Report:
- The market for Axillary Hyperhidrosis is expected to expand significantly between 2019 and 2032, with a strong CAGR during the forecast period.
- Dermata Therapeutics secured a key patent approval in Australia in February 2025 for its DMT410 program targeting hyperhidrosis, boosting its global IP portfolio.
- In June 2024, Botanix Pharmaceuticals received FDA approval for Sofdra (sofpironium) gel, 12.45%, making it the first and only new chemical entity approved in the US for treating primary axillary hyperhidrosis in individuals aged nine and older.
- InMode MD Ltd. introduced its InMode Pro System with Morpheus8 Applicator in January 2024—an RF-based solution designed specifically to address axillary hyperhidrosis.
- The US led the Axillary Hyperhidrosis market in 2022, registering an estimated market value of USD 500 million, with projections for continued growth.
- The condition affects roughly 2.8% of the US population, translating to nearly 7.8 million individuals, with about 50.8% experiencing axillary symptoms specifically.
- DelveInsight’s analysis estimates around 10.49 million cases of axillary hyperhidrosis in the US, with over 3.3 million diagnosed cases in 2021 alone.
- Severity-based data for 2021 revealed approximately 1.58 million with non-severe and 1.71 million with severe axillary hyperhidrosis.
- In Japan, the prevalence in individuals aged 5–64 years stands at 5.75%, with higher rates among males (6.60%) compared to females (4.72%).
Prominent Companies in the Axillary Hyperhidrosis Space:
- Botanix Pharmaceuticals
- Sound Surgical Technologies, LLC.
- Dr. August Wolff GmbH
- Medy-Tox
- Journey Medical Corporation
- Allergan, AbbVie, Dermata Therapeutics, and many others
Emerging Therapies in the Axillary Hyperhidrosis Market:
- Sofpironium Bromide (BBI-4000) – Botanix Pharma
- VASER – Sound Surgical Technologies
- Glycopyrronium Bromide – Dr. August Wolff GmbH
- Meditoxin – Medy-Tox
- Glycopyrronium Topical Wipes – Journey Medical Corporation
? To learn more about therapies poised to capture significant market share, click here: Axillary Hyperhidrosis Treatment Market
Understanding Axillary Hyperhidrosis
Axillary hyperhidrosis involves abnormal and excessive sweating in the underarm area, significantly impairing quality of life. It is a condition that goes beyond normal thermoregulatory sweating, often causing social anxiety and interference with daily routines.
?Get a Free sample for the Axillary Hyperhidrosis Market Report:
https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
Epidemiology Insights
The epidemiological analysis offers data-driven insights for the 7MM (US, EU4, UK, and Japan) from 2019 to 2032. It delves into total prevalence, severity segmentation, gender-based distribution, and diagnosis types (episodic vs. chronic cases).
? Understand what's shaping Axillary Hyperhidrosis epidemiology—download now:
Axillary Hyperhidrosis Epidemiology Forecast
Drugs Uptake and Pipeline Developments
This section examines current and pipeline therapies for Axillary Hyperhidrosis, with emphasis on market uptake rates, patient share, sales trends, and reasons for therapy preference. It also explores the RD landscape, including licensing activity, mergers, acquisitions, and innovation strategies by top companies.
Scope of the Report:
- Study Period: 2019–2032
- Geographies Covered: US, EU4, UK, Japan
- Therapeutic Assessment: Current emerging therapies
- Market Dynamics: Drivers, barriers, and opportunities
- Analytical Tools: SWOT, PESTLE, Porter’s Five Forces, and BCG Matrix
? Find more about companies advancing the Axillary Hyperhidrosis treatment space:
Axillary Hyperhidrosis Clinical Trials and Therapeutic Assessment
Table of Contents (Summary):
- Market Introduction
- Executive Summary
- SWOT Analysis
- Patient Share Overview
- Market Overview
- Disease Background
- Epidemiology and Trends
- Country-Wise Population Analysis
- Current Treatment Landscape
- Unmet Needs
- Emerging Therapies
- Market Forecast
- Country-wise Market Outlook
- Market Access and Reimbursement
- Market Drivers
- Market Challenges
- Appendix
- Research Methodology
- About DelveInsight
About DelveInsight
DelveInsight is a premier healthcare market research and consulting firm focused exclusively on the life sciences sector. With a robust portfolio of solutions ranging from pipeline assessment to market entry strategy and competitive intelligence, DelveInsight supports pharmaceutical companies in making informed business decisions to drive growth.
Contact Information
Kanishk
kkumar@delveinsight.com
info@delveinsight.com
+14699457679
